Clinical Trial: An Exploratory Clinical Study of CD19 BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy

U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06926985) titled 'An Exploratory Clinical Study of CD19 BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy' on April 08.

Brief Summary: A single arm, open-label pilot study is designed to evaluate the safety and effectiveness of CD19 BCMA CAR NK cells (KN5601) in patients with IgA nephropathy

Study Start Date: April 30

Study Type: INTERVENTIONAL

Condition: IgA Nephropathy (IgAN)

Intervention: DRUG: CD19 BCMA CAR NK cells

Patients will receive Fludarabine and Cyclophosphamide on day -5, -4, and -3. Multiple doses of CD19 CAR NK cells will infused using the dose-escalation strategy.

Recruitment Status: NOT_YET...